Rigakembaio to Receive Follow-up Milestone from Ono Pharmaceutical for ADC Joint Research
"Verifying the Pace of Pipeline Development Based on the ConjuAll(TM) Platform"
Rigakembaio announced on the 27th that it is scheduled to receive a follow-up development milestone under its antibody-drug conjugate (ADC) joint research agreement with Ono Pharmaceutical of Japan. The size of the milestone payment and detailed terms have not been disclosed in accordance with the contract.
This milestone is an additional achievement derived about one and a half months after the company received the previous one in January. The two companies had signed a joint research and candidate discovery agreement in October 2024, utilizing Rigakembaio's ADC platform, ConjuAll.
The designation of the first target was completed in March 2025. The company explained that the joint research is proceeding as planned, as it successively achieved stepwise development goals in January and February this year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Rigakembaio official stated, "Based on our collaboration with Ono Pharmaceutical, we are sequentially delivering the planned research and development outcomes." The official added that the company will seek to generate additional achievements from pipelines based on the ConjuAll platform.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.